Based on the results of previous phase I studies, in the current phase II trial we evaluated the efficacy and toxicity of cisplatin plus weekly docetaxel in the treatment of advanced non-small cell lung cancer (NSCLC).
Patients and methods
The eligibility criteria for the study included newly diagnosed stage IIIB/IV NSCLC, age ≤75 years, Eastern Cooperative Oncology Group performance status of 0-2, adequate organ functions, and signed informed consent. The chemotherapy regimen consisted of cisplatin, 80 mg/m2 on day 1, and docetaxel, 25 mg/m2 on days 1, 8 and 15 every 4 weeks.
Results
Between January 2002 and December 2003, 31 patients with NSCLC were enrolled in the study. An objective response rate of 40% (95% CI, 21-60) was obtained in 27 assessable patients. The median time to progression was 6.4 months (range, 2.5-26.3) and median overall survival was 10.01 months (range, 5-28.3). The regimen was well tolerated with no grade 4 toxicity.
Conclusions
Cisplatin plus weekly docetaxel is an effective and well-tolerated regimen in chemo-naive patients with advanced NSCLC. A phase III study of weekly versus the conventional regimen of every three weeks should be conducted to compare the survival benefits, toxicity profile and quality of life.
JemalA., MurrayT., SamuelsA., GhafoorA., WardE., ThunM.J.: Cancer statistics, 2003.CA Cancer J Clin, 53: 5–26, 2003.
2.
Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials.Br Med J, 311: 899–909, 1995.
3.
SchillerJ.H., HarringtonD., BelaniC.P., LangerC., SandlerA., KrookJ., ZhuJ., JohnsonD.H., Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer.N Engl J Med, 10: 92–98, 2002.
4.
RoszkowskiK., PluzanskaA., KrzakowskiM., SmithA.P., SaigiE., AaseboU., ParisiA., Pham TronN., OlivaresR., BerilleJ.: A multicenter, randomised, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naïve patients with metastatic or non-re-sectable localized non-small cell lung cancer (NSCLC).Lung Cancer, 27: 145–157, 2000.
5.
ShepherdF.A., DanceyJ., RamlauR., MattsonK., GrallaR., O'RourkeM., LevitanN., GressotL., VincentM., BurkesR., CoughlinS., KinY., BerilleJ.: Prospective randomised trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy.J Clin Oncol, 18: 2095–2103, 2000.
6.
FossellaF.V., DeVoreR., KerrR.N., CrawfordJ., NataleR.R., DunphyF., KalmanL., MillerV., LeeJ.S., MooreM., GandaraD., KarpD., VokesE., KrisM., KimY., GamzaF., Hammer-shaimbL.: Randomized phase III trial of docetaxel versus vi-norelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens.J Clin Oncol, 18: 2354–2362, 2000.
7.
MillwardM.J., ZalcbergJ., BishopJ.F., WebsterL.K., ZimetA., RischinD., TonerG.C., LairdJ., CosoloW., UrchM., BrunoR., LoretC., JamesR., BlancC.: Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small cell lung cancer.J Clin Oncol, 15: 750–758, 1997.
8.
ZalcbergJ., MillwardM., BishopJ.F., McKeageM., ZimetA., TonerG., FriedlanderM., BarterC., RischinD., LoretC., JamesR., BouganN., BerilleJ.: Phase II study of docetaxel and cisplatin in advanced non small cell lung cancer.J Clin Oncol, 16: 1948–1953, 1998.
9.
FossellaF., PereiraJ.R., von PawelJ., PluzanskaA., GorbounovaV., KaukelE., MattsonK.V., RamlauR., SzczesnaA., FidiasP., MillwardM., BelaniC.P.: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorel-bine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 Study Group.J Clin Oncol.21: 2354–2362, 2000.
10.
KubotaK., WatanabeK., KunitohH., NodaK., IchinoseY., KatakamiN., SugiuraT., KawaharaM., YokoyamaA., YokotaS., YonedaS., MatsuiK., KudoS., ShibuyaM., IsobeT., SegawaY., NishiwakiY., OhashiY., NiitaniH.: Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small cell lung cancer: the Japanese Taxotere Lung Cancer Study Group.J Clin Oncol, 22: 254–261, 2004.
11.
KunitohH., WatanabeK., OnoshiT., FuruseK., NiitaniH., TaguchiT.: Phase II trial of docetaxel in previously untreated advanced non-small cell lung cancer: a Japanese cooperative study.J Clin Oncol, 14: 1649–1655, 1996.
HainsworthJ.D., BurrisH.A., ErlandJ.B., ThomasM., GrecoF.A.: Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.J Clin Oncol, 16: 2164–2168, 1998.
14.
HainsworthJ.D., BurrisH.A., LitchyS., MorrisseyL.H., BartonJ.H., BradofJ.E., GrecoF.A.: Weekly docetaxel in the treatment of elderly patients with advanced non-small cell lung carcinoma.Cancer, 89: 328–333, 2000.
15.
MillerA.B., HoogstratenB., StaquetM., WinklerA.: Reporting results of cancer treatment.Cancer, 47: 207–214, 1981.
SimonR.: Optimal two-stage designs for phase II clinical trials.Control Clinical Trials10: 1–10, 1989.
18.
KaplanE.L., MeierP.: Nonparametric estimation from incomplete observations.J Am Stat Assoc, 53: 457–481, 1958.
19.
SatoshiT., MinatoK., WatanabeS., TakeiY., IshiharaS., SatoK., KobayashiG., ToiA., KairaK., IwasakiY., UtugiM., SaitoR.: A phase I study of cisplatin (CDDP) and weekly docetaxel (DCT) in advanced non-small cell lung cancer (NSCLC).Proc ASCO, 19: 531 A, abst no. 2087, 2000.
20.
KoizumiT., TsunodaT., FujimotoK., NomuraH., HiraiK., KoyamaS., OkadaK., KuboK.: Phase I trial of weekly docetaxel combined with cisplatin in patients with non-small cell lung cancer.Lung Cancer, 34: 125–131, 2001.
21.
TsunodaT., KoizumiT., HayasakaM., HirayK., KoyamaS., TakabayashiY., FujimotoK., KuboK.: Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small cell lung cancer.Cancer Chemother Pharmacol, 54: 173–177, 2004.
22.
OheY., NihoS., KakinumaR., KubotaK., OhmatsuH., GotoK., NokiharaH., KunitohH., SaijoN., AonoH., WatanabeK., TangoM., YokoyamaA., NishiwakiY.: A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small cell lung cancer in elderly patients.Ann Oncol, 15: 45–50, 2004.
23.
MinamiH., OheY., NihoS., GotoK., OhmatsuH., KubotaK., KakinumaR., NishiwakiY., NokiharaH., SekineI., SaijoN., HanadaK., OgataH.: Comparison of pharmacokinetics and pharmacodynamics of docetaxel and cisplatin in elderly and nonelderly patients: why is toxicity increased in elderly patients?J Clin Oncol, 22: 2901–2908, 2004.
